Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afamelanotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R known ✓ | Q01726 | 2/20 | 0.80 |
| ▸ | MC4R | P32245 | 3/20 | 0.80 |
| ▸ | MC5R | P33032 | 2/20 | 0.80 |
| ▸ | MC3R | P41968 | 2/20 | 0.80 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.71 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.65 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CTSH | P09668 | 1/20 | 0.61 |
| ▸ | NMBR | P28336 | 1/20 | 0.60 |
| ▸ | GRPR | P30550 | 1/20 | 0.60 |
| ▸ | TFPI | P10646 | 2/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.59 |
| ▸ | GLP1R | P43220 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afamelanotide SCHEMBL22463811 | 1.00 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29419548 | 1.00 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29352792 | 1.00 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL22463810 | 1.00 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29970570 | 0.97 | MC4R (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL18281742 | 0.96 | MC4R (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL30312751 | 0.96 | MC4R (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29533782 | 0.96 | C5AR1 (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL18281737 | 0.96 | MC4R (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL22076809 | 0.95 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20250302823-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2025-10-02 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250228827-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2025-07-17 | — | — | US | claimed |
| EP-4531854-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2025059425-A1 | GLYT-1 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20240390362-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | DISC MEDICINE, INC. | 2024-11-28 | — | — | US | claimed |
| US-20240366574-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2024-11-07 | — | — | US | claimed |
| CN-118171031-A | Power distribution network expansion planning method and system for promoting digestion capacity improvement | 南京工程学院 | 2024-06-11 | — | — | CN | claimed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| EP-4347023-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Disc Medicine, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4337199-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023235326-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | claimed |
| WO-2022251458-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | DISC MEDICINE, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| CN-115360764-A | Power distribution network dynamic partitioning method based on multi-objective ant colony optimization | 福州大学 | 2022-11-18 | — | — | CN | claimed |
| WO-2022241274-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4087570-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302823-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | SLC10A1, GFPT1, GLS2 | MC1R 2171/4885MC4R 3377/4885MC5R 3901/4885 |
| US-20250228827-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | MC1R 1610/4885MC4R 3402/4885MC5R 4059/4885 |
| US-20240390362-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | PRCP, PAXBP1, PPOX | MC1R 948/4885MC4R 1870/4885MC5R 1695/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | MC1R 92/4885MC4R 56/4885MC5R 140/4885 |
| US-20240366574-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | MC1R 1495/4885MC4R 3580/4885MC5R 3974/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | MC1R 1610/4885MC4R 3402/4885MC5R 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.